Tag: bepirovirsen
Experimental Drug Shows 96% Viral Suppression in Hepatitis B Clinical Trial
Clinical trial shows experimental drug bepirovirsen achieves 96% viral suppression when combined with standard hepatitis B therapy. Phase III trials…
Phase 3 Trial of Bepirovirsen Shows Promise for Chronic Hepatitis B Treatment
Phase 3 clinical trial results for bepirovirsen, a novel antisense oligonucleotide therapy for chronic hepatitis B, published in The New…
Experimental GSK drug achieves functional hepatitis B cure in 1 in 5 patients
GSK's experimental drug bepirovirsen achieved functional hepatitis B cure in 18% of patients during phase 2 trials, vastly outperforming current…
Submit Your Paper to GMJ
No APC until January 2027.